Walleye Capital’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Walleye Capital’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-60,012	Closed	-$2.31M	–	5552
2023 Q2	$2.31M	Sell	60,012 -334,088	-85%	-$8.58M	0.01%	1236
2023 Q1	$9.12M	Buy	394,100 +262,725	+200%	+$6.26M	0.14%	162
2022 Q4	$3.44M	Sell	131,375 -166,009	-56%	-$3.68M	0.06%	364
2022 Q3	$5.85M	Buy	297,384 +20,846	+8%	+$418K	0.11%	200
2022 Q2	$4.84M	Buy	276,538 +103,035	+59%	+$1.62M	0.13%	180
2022 Q1	$2.84M	Sell	173,503 -3,048	-2%	-$41.4K	0.08%	269
2021 Q4	$2.88M	Buy	+176,551	New	+$2.51M	0.09%	246
2021 Q3	–	Sell	-16,567	Closed	-$234	–	1888
2021 Q2	$234	Buy	+16,567	New	+$265K	0.01%	1024
2020 Q3	–	Sell	-12,852	Closed	-$148K	–	1008
2020 Q2	$148K	Buy	12,852 +8,652	+206%	+$119K	0.03%	471
2020 Q1	$57K	Buy	+4,200	New	+$49.7K	0.01%	676

Walleye Capital's KDNY Position: Q3 2023 in Review

Walleye Capital sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 60,012 shares — an estimated $2.31M sold.

Walleye Capital first reported a position in KDNY in Q1 2020 and held it in 10 quarters. The position peaked at $9.12M in Q1 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.

Walleye Capital reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Walleye Capital sold 60,012 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $2.31M.
Walleye Capital first reported a position in Chinook Therapeutics, Inc. Common Stock in Q1 2020 and held it in 10 quarters.
Walleye Capital's Chinook Therapeutics, Inc. Common Stock position peaked at $9.12M in Q1 2023.
2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Walleye Capital's 13F filing for Q3 2023, filed 14 Nov 2023.